Collegium Pharmaceutical (NASDAQ:COLL) received a $26.00 price objective from equities research analysts at Janney Montgomery Scott in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target would indicate a potential upside of 21.33% from the stock’s previous close.
Several other research firms have also recently issued reports on COLL. Piper Jaffray Companies set a $33.00 price objective on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Monday, November 13th. Jefferies Group raised their target price on shares of Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th. Needham & Company LLC raised their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th. They noted that the move was a valuation call. Finally, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $25.17.
Collegium Pharmaceutical (COLL) traded up $0.08 during trading on Tuesday, hitting $21.43. 494,826 shares of the stock traded hands, compared to its average volume of 592,025. The company has a market capitalization of $697.81 and a PE ratio of -7.22. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $26.77.
In related news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $17.34, for a total value of $17,340,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Insiders have sold 1,105,558 shares of company stock valued at $19,346,677 over the last 90 days. 25.76% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Teton Advisors Inc. boosted its stake in Collegium Pharmaceutical by 18.5% in the 4th quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock worth $591,000 after purchasing an additional 5,000 shares during the period. Monarch Partners Asset Management LLC acquired a new position in Collegium Pharmaceutical in the 4th quarter worth approximately $264,000. Granite Investment Partners LLC boosted its stake in Collegium Pharmaceutical by 34.1% in the 4th quarter. Granite Investment Partners LLC now owns 69,920 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after purchasing an additional 17,784 shares during the period. Rice Hall James & Associates LLC boosted its stake in Collegium Pharmaceutical by 489.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 332,587 shares of the specialty pharmaceutical company’s stock worth $6,140,000 after purchasing an additional 276,123 shares during the period. Finally, First Manhattan Co. acquired a new position in Collegium Pharmaceutical in the 4th quarter worth approximately $8,606,000. 82.29% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Janney Montgomery Scott Analysts Give Collegium Pharmaceutical (COLL) a $26.00 Price Target” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/06/janney-montgomery-scott-analysts-give-collegium-pharmaceutical-coll-a-26-00-price-target.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.